<DOC>
	<DOC>NCT02577783</DOC>
	<brief_summary>The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.</brief_summary>
	<brief_title>PDD vs PAD to Treat Initially Diagnosed MM</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnosed and untreated multiple myeloma patients Patients with age between 18 and 70 years With a evaluable disease ECOG score ≤2 NE≥1.0×10E9 /L, Plt≥50×10E9 /L, Hb≥70 g/L AST, ALT, ALP≤3×ULN, serum BIL≤ULN LVEF≥ 50% Not in pregnancy Written informed consent are acquired Severe heart failure (NYHA grade II or higher) Active and uncontrolled severe infection HIV positive Have accepted any other antitumor drug within 30 days before the first dose of doxorubicin hydrochloride iposome or doxorubicin Grade 2 or higher peripheral neuropathy before treatment Have suffered any other malignancy in past 5 years Females in lactation Other situations that investigators consider as contraindication for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Doxorubicin Hydrochloride</keyword>
</DOC>